Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending March 2013. The report serves as a notification of transactions involving directors and persons discharging managerial responsibilities under the GlaxoSmithKline Annual Investment Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is limited to reporting specific director share transactions.
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document details the exercise of share awards by Dr. M. M. Slaoui on March 15, 2013, at a price of 1,495 pence per share.
Guidance, Outlook, and Risks
The filing contains no management commentary, guidance, outlook, or discussion of risks and contingencies. It strictly reports a transaction notified in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).
Important Facts for Investors
- Dr. M. M. Slaoui exercised a total of 25,981 ordinary shares from awards granted between 2003 and 2006.
- The exercise price was 1,495 pence per share.
- 11,715 ordinary shares were sold on March 18, 2013, at 1,495.50 pence per share to cover tax obligations.
- The transaction was reported to the SEC on March 19, 2013.